Tau predicts cognitive impairment in a prospective longitudinal CSF study in Parkinson’s Disease
Objective: We hypothesize that CSF profiles of Aβ and Tau (total and phosphorylated) are associated with clinical subtypes and disease progression. Background: Parkinson’s disease (PD)…Cognitive impairment in early onset and familial Parkinson’s disease.
Objective: The Parkinson’s Families Project (PFP) is a large-scale cohort of early onset (symptom onset <45) and familial Parkinson’s disease (PD) patients. One aim of…What impacts relationship satisfaction in Parkinsonian dementias?
Objective: To explore which aspects of well-being impact on marital relationship satisfaction among people with Parkinsonian dementias and their spouses. Background: Dyadic relationships in Parkinson’s disease…Development and validation of an alternative version of the Parkinson’s Disease-Cognitive Rating Scale
Objective: To develop and validate an alternative form of the PD-CRS (PD-CRS/AF) with the objective of providing a reliable and fully equivalent method of reassessment…SNCA multiplication consortium: Clinicogenetic analysis of SNCA multiplication probands and families.
Objective: Clinicogenetic analysis of 57 affected probands with SNCA multiplication, 3 unaffected carriers, and their 60 families. To use informative pedigrees to identify penetrance modifiers…Validation of the performance based Erlangen Test of Activities of Daily Living in PD
Objective: The Erlangen Test of Activities of Daily Living (E-ADL) is a performance-based test to assess the activity of daily living (ADL) dysfunction associated with…Patient-reported hallucinations and the probability of progression to dementia in Parkinson’s disease
Objective: To evaluate the influence of neuropsychiatric symptoms in identifying Parkinson’s disease (PD) patients who will progress to dementia (PDD) in the imminent future (~4…Association of the GBA T369M polymorphism with motor and cognitive symptoms in Parkinson’s disease
Objective: To determine whether the GBA polymorphism T369M is associated with earlier age of onset, lower cognitive performance, and more severe motor impairment in Parkinson's…Use of pimavanserin in patients with Parkinson’s disease psychosis: Subgroup analysis of efficacy and safety in patients with and without cognitive impairment
Objective: A planned subgroup analysis of a phase 3 study was performed to evaluate the efficacy and safety of pimavanserin (PIM) in Parkinson’s disease psychosis…Self-awareness of cognitive functions in Parkinson’s disease patients with and without mild cognitive impairment.
Objective: To examine whether Parkinson’s disease (PD) patients with or without mild cognitive impairment (MCI) show impaired self-awareness (ISA) of their cognitive abilities. Background: PD…
- « Previous Page
- 1
- …
- 24
- 25
- 26
- 27
- 28
- …
- 36
- Next Page »